Melanoma CME

This activity is expired and is no longer available for CME credit.


Ipilimumab versus Placebo After Complete Resection of Stage III Melanoma: Results from the EORTC 18071 Phase III Trial

Author(s)/Faculty: Alexander M.M. Eggermont, MD, PhD
Release Date: 11/6/2015Expiration Date: 11/5/2016
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
In this CME activity, Dr. Alexander Eggermont discusses the EORTC 18071 phase III clinical trial of adjuvant ipilimumab versus placebo after complete resection of stage III melanoma at high risk of recurrence.